Transplantation of iPSC-derived TM cells rescues glaucoma phenotypes in vivo

Wei Zhu1,a,b, Oliver W. Gramlich3, Lauren Laboissonnierè, Ankur Jain4, Val C. Sheffield2,d,e, Jeffrey M. Trimarchi3, Budd A. Tucker1, and Markus K. Kuehn1,a,b,1

*Department of Ophthalmology and Visual Sciences, University of Iowa, Iowa City, IA 52242; 1Department of Genetics, Development, and Cell Biology, Iowa State University, Ames, IA 50011; 2Department of Pediatrics, University of Iowa, Iowa City, IA 52242; and 3Howard Hughes Medical Institute, University of Iowa College of Medicine, Iowa City, IA 52242

Edited by David J. Calkins, Vanderbilt University Medical Center, Nashville, TN, and accepted by Editorial Board Member Jeremy Nathans May 4, 2016 (received for review March 17, 2016)

Glaucoma is a common cause of vision loss or blindness and reduction of intraocular pressure (IOP) has been proven beneficial in a large fraction of glaucoma patients. The IOP is maintained by the trabecular meshwork (TM) and the elevation of IOP in open-angle glaucoma is associated with dysfunction and loss of the postmitotic cells residing within this tissue. To determine if IOP control can be maintained by replacing lost TM cells, we transplanted TM-like cells derived from induced pluripotent stem cells into the anterior chamber of a transgenic mouse model of glaucoma. Transplantation led to significantly reduced IOP and improved aqueous humor outflow facility, which was sustained for at least 9 wk. The ability to maintain normal IOP engendered survival of retinal ganglion cells, whose loss is ultimately the cause for reduced vision in glaucoma. In vivo and in vitro analyses demonstrated higher TM cellularity in treated mice compared with littermate controls and indicated that this increase is primarily because of a proliferative response of endogenous TM cells. Thus, our study provides in vivo demonstration that regeneration of the glaucomatous TM is possible and points toward novel approaches in the treatment of this disease.

Significance

The regulation of intraocular pressure (IOP) is vital for the health of the eye. Failure to maintain IOP frequently leads to vision loss in glaucoma. The IOP is maintained by the trabecular meshwork (TM), which exhibits decreased cellular density with age and disease. Here we demonstrate that induced pluripotent stem cells differentiated into TM cells (designated iPSC-TM) restore TM function for over 9 wk, regulate IOP, and prevent neuronal loss in a glaucoma mouse model. Transplanted iPSC-TM survive in the TM, but the most pronounced effect of transplantation is a robust proliferative response of endogenous TM cells. These findings suggest that lasting restoration of IOP control through iPSC-TM transplantation is possible and may represent a novel treatment approach for glaucoma.

Author contributions: W.Z., B.A.T., and M.H.K. designed research; W.Z., O.W.G., L.L., A.J., and J.M.T. performed research; L.L., A.J., V.C.S., J.M.T., B.A.T., and M.H.K. contributed new reagents/analytic tools; W.Z., O.W.G., L.L., A.J., V.C.S., J.M.T., B.A.T., and M.H.K. analyzed data; and W.Z., O.W.G., V.C.S., and M.H.K. wrote the paper.

The authors declare no conflict of interest.

This article is a PNAS Direct Submission. D.J.C. is a guest editor invited by the Editorial Board.

1To whom correspondence should be addressed. Email: markus-kuehn@uiowa.edu.

This article contains supporting information online at www.pnas.org/lookup/suppl/doi:10.1073/pnas.1604153113/-/DCSupplemental.
TM cells (19, 20). One well-documented effect of laser trabecu-lopasty is that it causes an increase in TM cell division, leading to the conclusion that the laser burn induces a repair process by repopulating a cell deficient TM (21, 22).

We previously demonstrated that induced pluripotent stem cells (iPSC) can be differentiated into a cell type, designated iPSC-TM, which resembles primary TM cells (pTM) (23). iPSC-TM are morphologically very similar to pTM, express a large number of proteins characteristic of TM, and functionally respond to various stimuli in a manner typical of TM cells. Herein we provide functional data to demonstrate that transplantation of iPSC-TM into a mouse model of glaucoma can restore IOP control and prevent RGC degeneration. These studies were aided by the development of a transgenic mouse model of glaucoma because of expression of human myocilin with the disease causing mutation Y437H (Tg-MYOC<sup>Y437H</sup>) (24, 25). The eyes of these mice develop normally, and structural damage to the TM is modest, but significant loss of TM cells, elevated IOP, and subsequent RGC loss is observed as animals age (24). Thus, this mouse model provides an unparalleled opportunity to examine TM function following iPSC-TM transplantation. However, because loss and dysfunction of TM cells is observed in all forms of open angle glaucoma, it is possible that transplantation of iPSC-TM will be of benefit to a much larger group of individuals than those with mutations in MYOC.

**Results**

**Preparation and Characterization of iPSC-TM.** As we have shown previously, iPSC can be induced to differentiate into a cell type (iPSC-TM) that strongly resembles pTM morphologically, functionally, and compositionally (23). Here, mouse iPSC-TM were induced from iPSC derived from fibroblasts isolated from transgenic animals constitutively expressing the cellular marker dsRed. iPSC were seeded and, when confluency reached 5%, induced to differentiate by maintaining them in biopsy media previously conditioned by primary human TM cells. This approach induces distinct morphological changes in the cultured cells (Fig. 1A). iPSC grow in colonies of high cellular density and the ratio of nuclei to cytoplasm is much higher than that of other cells types. However, after 7-d differentiation, developing iPSC-TM have separated from the colonies, begin to exhibit spindle-like morphology, and resemble primary cultured TM cells although they are smaller at this stage. iPSC-TM continue to grow and after 14 d of differentiation are of similar size and exhibit the typical morphology of pTM.

The transition to an iPSC-TM phenotype is accompanied by profound changes in gene expression. After 14 d of differentiation, increasing numbers of iPSC-TM are immunopositive for laminin A4 (Lama4) and tissue inhibitor of matrix proteases 3 (Timp3), molecules that are prominently expressed in native TM cells, but not iPSC (Fig. 1B). These findings are supported by gene-expression analysis, demonstrating that expression of Lama4 and Timp3 increases during the transition from iPSC to iPSC-TM (Fig. 1C). Conversely, the iPSC biomarkers Nanog homeobox (Nanog) and SRY box 2 (Sox2) exhibit a progressive decrease in expression levels during this process.

We’ve also previously demonstrated that iPSC-TM respond to exposure to glucocorticoids with enhanced synthesis and secretion

![Fig. 1. Characterization of iPSC-TM. (A) Morphology of undifferentiated iPSCs (0 d) and iPSC-TM after 7- and 14-d differentiation. (B) Immunohistochemical detection of TM biomarkers LAMA4 and TIMP3 (green) in iPSC (0 d) and iPSC-TM after 7- or 14-d differentiation. Nuclei were stained with DAPI (blue). (C) Fold-change of iPSCs biomarkers (Nanog and Sox2) and (LAMA4 and TIMP3) in iPSCs and iPSC-TM after 7- and 14-d differentiation. *P < 0.05. (Scale bars, 100 μm.)](https://www.pnas.org/content/early/2016/06/06/1605402113)
Fig. 2. Formation of CLANs in iPSC-TM. (A) High-magnification example of CLANs in iPSC-TM following 14-d differentiation and Dex treatment. Cells were stained with phalloidin and DAPI (blue). (B) Optical sections demonstrating the dome-shaped organization of iPSC-TM forming CLANs. The distance between each scan is 0.5 μm. An arrow has been inserted highlighting one cell to facilitate orientation. (C) Formation of CLANs in iPSC (left) and 14 d differentiated iPSC-TM in the vehicle control (center), and Dex treatment (right) groups. Arrowheads highlight several, but not all, cells forming CLANs. (Scale bars, 100 μm.) (D) Quantitation of iPSC-TM forming CLANs in undifferentiated iPSC vehicle controls (n = 3) and Dex-treated cells (n = 3). *P < 0.05 vs. vehicle control.

of myocilin (23). Another well-characterized response of TM cells to glucocorticoid exposure is the formation of cross-linked actin networks (CLANs) (26). These cytoskeletal structures form geodesic dome-like polygonal lattices and can be discriminated from temporary arrangements of polygonal actin structures based on the cell’s size and the height (Fig. 2 A and B). Previously published studies indicate that ~14% of human pTM and 30% of mouse pTM cells form CLANs (26, 27). Here, iPSC-TM were differentiated for 14 d and subsequently exposed to 100 nM dexamethasone (Dex) for 3 additional days. Controls included uninduced iPSC and iPSC-TM treated with vehicle only. Our findings demonstrate that CLANs are not observed in undifferentiated iPSC (Fig. 2C). However, Dex treatment of iPSC-TM resulted in CLAN formation in 23.62 ± 2.28% of all cells, whereas only 12.5% ± 0.48 of vehicle-treated iPSC-TM responded in this fashion (P = 0.041). These data provide additional support to our previous findings that our differentiation approach yields iPSC-TM that resemble pTM in many important aspects.

Purification of iPSC-TM. The formation of tumors as a result of the presence of remaining pluripotent cells is a significant safety concern for in vivo studies using iPSC. To produce iPSC-TM cells appropriate for transplantation, we used a negative-selection approach by removing cells still expressing markers of pluripotency from the iPSC-TM population. After differentiation for 14 d, stage-specific mouse embryonic antigen 1 positive (SSEA-1+) cells were depleted using SSEA-1–conjugated magnetic beads. In our hands four successive rounds of purification are required to remove all SSEA-1+ cells (Table 1). Elimination of these cells is a crucial aspect of this experimental approach. Transplantation of 50,000 iPSC-TM to the anterior chamber of normal recipient mice resulted in tumor formation in over 7% of all eyes using the twice-purified cell population containing 3% SSEA-1+ cells. However, four rounds of purification effectively removed all SSEA-1+ cells and transplantation of this fraction did not result in tumor formation in any of the treated mice.

iPSC-TM purified in this manner can be further maintained in vitro. iPSC-TM continue to express the dsRed transgene and retain a morphological appearance similar to pTM cells (Fig. S1). These data demonstrate that meticulous removal of iPSC with remaining pluripotency is essential for use in vivo but also that multiple rounds of magnetic separation are effective in creating a stable and safe population of cells for transplantation.

Time Course of Damage in Tg-MYOCLU437H Mice. These studies relied on the use of a transgenic mouse model of glaucoma. These animals constitutively express human myocilin harboring a pathogenic mutation (Tg-MYOCLU437H) and display multiple glaucomatous phenotypes, including TM cell loss, elevated IOP, and progressive RGC loss (24). To further define the pathological stages of this mouse model and to identify a suitable age for transplantation, we improved upon our previously published data (24) by obtaining detailed data for IOP, aqueous humor outflow facility, and TM cellularity in 2-, 4-, and 6-mo-old Tg-MYOCLU437H mice, as well as in age-matched WT littermate controls (Fig. 3A). Congruent with our previous findings, IOP in 2-mo-old Tg-MYOCLU437H mice does not differ from that observed in control animals. However, IOP does increase with age in transgenic mice and, although IOP is slightly elevated at age 4 mo (15.1 ± 0.3 mmHg vs. 13.9 ± 0.5 mmHg, P = 0.037), the difference becomes readily apparent by age 6 mo (15.8 ± 0.7 mmHg vs. 13.9 ± 0.5 mmHg, P = 0.0019).

Measurements of aqueous humor outflow facility are more sensitive in unmasking subtle disturbances in aqueous humor drainage. We used this approach in the same groups of control and Tg-MYOCLU437H mice (Fig. 3B). As reported elsewhere (28), we observed comparatively low outflow facility in young animals. In WT mice aqueous humor outflow facility increases between 2 and 4 mo of age (0.016 ± 0.008 and 0.029 ± 0.006 μL·min·mmHg, respectively) but remains stable thereafter (0.030 ± 0.013 μL·min·mmHg in 6-mo-old WT mice). In Tg-MYOCLU437H mouse outflow facility resembles that of young normal mice at a young age (0.017 ± 0.009 μL·min·mmHg) but, analogous to our observations for IOP, deficiencies become apparent in 4-mo-old animals (0.024 ± 0.011 μL·min·mmHg) and are statistically significant by age 6 mo (0.014 ± 0.0007 μL·min·mmHg, P = 0.0124).

The development of aqueous humor outflow deficiencies is accompanied by a progressive decrease in the cellular density of the TM. Although the anterior segment, including the TM, develops normally in transgenic animals, expression of MYOCLU437H leads to endoplasmic reticulum stress and TM cell loss (24). To further define this process, we determined TM density, defined as nuclei contained within the collagen IV immunoreactive tissue overlying the Schlemm’s canal in 4- and 6-mo-old Tg-MYOCLU437H and control mice (Fig. 3C). Data obtained demonstrate that at the

| Rounds of purification | SSEA-1+ cell ratio (%) | Teratoma formation |
|-----------------------|------------------------|--------------------|
| 1                     | 39.2                   | 66.6% (8/12)       |
| 2                     | 3.0                    | 7.14% (1/14)       |
| 3                     | 0.0                    | 0.0% (0/14)        |

Quantitation of SSEA-1+ cells after one, two, and four rounds of purification and corresponding tumor formation ratios following anterior chamber injection in Tg-MYOCLU437H mice (n = 12, 14, and 14, respectively).
Fig. 3. Development of pathology in Tg-MYOC<sup>Y437H</sup> mice. (A) IOP in 2-, 4-, and 6-mo-old Tg-MYOC<sup>Y437H</sup> mice (n = 9, 47, and 20, respectively) and age-matched WT littersmates (n = 7, 24, 31, respectively). (B) Outflow facility in 2-, 4-, and 6-mo-old Tg-MYOC<sup>Y437H</sup> mice (n = 6, 13, and 8, respectively) and age-matched controls (n = 6, 6, and 6, respectively). (C) Immunohistochemical detection of collagen IV (Col, red) and DAPI (blue) in the anterior segment of 6-mo-old WT and MYOC transgenic (Tg) mice. For the purpose of this study, the TM is defined as the Col IV region overlying the Schlemm’s canal. (D) Quantitation of TM cells number in 4- and 6-mo-old Tg-MYOC<sup>E3495</sup> mice (n = 26 and 8, respectively) and age-matched controls (n = 14 and 6, respectively). *P < 0.05. (Scale bars, 100 μm.)

age of 4 mo very few TM cells have been lost in transgenic animals (42.8 ± 8.6 cells vs. 46.3 ± 7.1 cells, P = 0.09), but a marked loss is readily apparent at 6 mo (33.1 ± 9.5 vs. 45.8 ± 4.8 cells, P = 0.007) (Fig. 3D). The age of pronounced TM cell loss is consistent with that at which functional deficits become apparent and further demonstrates that the disruption of outflow facility in Tg-MYOC<sup>Y437H</sup> mice is a degenerative process, as opposed to a developmental deficit. Minor effects of the mutation are apparent at 4 mo of age, suggesting the onset of the degenerative process, but disruption of aqueous humor dynamics accelerates thereafter and becomes statistically significant in all parameters evaluated here.

iPSC-TM Transplantation in Vivo. Based upon our observation that 4-mo-old Tg-MYOC<sup>Y437H</sup> mice exhibit the first signs of TM cell loss, we sought to determine whether aqueous humor dynamics can be preserved through the transplantation of iPSC-TM derived from healthy mice. Therefore, 50,000 purified iPSC-TM were injected into the anterior chamber of 4-mo-old Tg-MYOC<sup>Y437H</sup> mice in a volume of 3 μL PBS (n = 22). Additionally, we injected an equal number of fibroblasts, a cell type known to secrete growth factors that can support TM cell survival, in a second group of transgenic mice (n = 8). Transgenic animals receiving an injection of an equal volume of PBS served as controls (vehicle control, n = 16). In addition, age-matched WT mice (n = 20) were used. IOP and outflow facility were determined before transplantation, as well as 6 and 9 wk after injection (5.5 and 6.25 mo of age).

Consistent with the data shown above, the group of transgenic animals used for these transplantation studies displayed minor differences in IOP at the age of 4 mo compared with the WT controls (14.4 ± 1.8 mmHg vs. 13.6 ± 1.6 mmHg) (Fig. 4A). Similarly, whereas minor differences in the aqueous humor outflow facility were apparent, statistical significance was not yet reached (0.024 ± 0.01 vs. 0.029 ± 0.006 μL·min·mmHg, P = 0.2) (Fig. 4B). As expected, 6-wk later the IOP had risen and the aqueous humor outflow facility had markedly decreased in vehicle control-injected transgenic animals (16.4 ± 3.1 mmHg and 0.014 ± 0.005 μL·min·mmHg). In contrast, IOP and outflow facility in iPSC-TM recipient eyes resembled that of WT mice (12.6 ± 3.7 mmHg and 0.025 ± 0.01 μL·min·mmHg) and were significantly better that those determined in the vehicle control group (P = 0.001 and 0.02, respectively). IOP remained significantly lower in iPSC-TM-treated animals than in vehicle control mice until the last measurement was taken 9 wk after transplantation (12.2 ± 2.8 mmHg, P = 0.0006). At this point, aqueous humor outflow facility also continued to be significantly higher in iPSC-TM recipient animals compared with PBS control mice (0.027 ± 0.01 vs. 0.011 ± 0.005 μL·min·mmHg, P = 0.017).

Transplantation of fibroblasts provided a minor improvement of IOP and outflow facility, although a statistically significant rescue effect compared with the vehicle control group could not be demonstrated for either measure. IOP and outflow facility in these mice were at 14.5 ± 3.5 mmHg (P = 0.15) and 0.022 ± 0.01 μL·min·mmHg (P = 0.09) 6 wk after transplantation. After 9 wk, IOP had slightly increased (14.6 ± 3.0 mmHg, P = 0.17) and outflow facility declined to 0.016 ± 0.013 μL·min·mmHg (P = 0.45). However, because of the slightly improved outflow dynamics, values obtained in fibroblast-injected mice are also not statistically different from those of WT mice (P = 0.27 and 0.22 for outflow facility and 0.7 and 0.6 for IOP at 6 and 9 wk, respectively).

Reduction of IOP to achieve RGC survival is a mainstay of clinical glaucoma therapy. Importantly, in iPSC-TM recipient eyes the reduction of IOP also resulted in RGC rescue. Mice were killed 12 wk after transplantation and surviving RGC were identified through γ-synuclein immunoreactivity (Fig. 4C). Although this approach relies on continuous expression of this RGC marker, we and others have found a high correlation between RGC numbers and optic nerve damage (24, 29–34). Data obtained here demonstrate that eyes of vehicle control Tg-MYOC<sup>Y437H</sup> animals display a significantly lower RGC density than those of WT controls (1706.9 ± 491.3 RGC/mm<sup>2</sup> vs. 2171.9 ± 186.3 RGC/mm<sup>2</sup>, P = 0.027). In contrast, iPSC-TM recipient eyes of transgenic mice display a RGC density similar to WT mice and significantly higher density than the vehicle control group (2222.1 ± 250.4 RGC/mm<sup>2</sup>, P = 0.041). A protective effect was not apparent in the fibroblast group (1675.6 ±
77.6 RGC/mm², \( P = 0.92 \) (Fig. 4D). Taken together, these data demonstrate that intraocular injection of iPSC-TM prevents IOP elevation and aqueous humor outflow reduction and results in preservation of RGC density in Tg-MYOC\(^{Y437H}\) mice.

**Cellular Effects of iPSC-TM in Vivo.** To estimate iPSC-TM survival in vivo and to gain insight into the consequences of transplantation, we determined both native TM cell and iPSC-TM density in study animals. The immunohistochemical analysis of sagittal sections of the anterior segment of iPSC-TM recipient eyes demonstrate that iPSC-TM integrate into the TM and survive for at least 12 wk until the end of the study period (Fig. 5A). Off-target integration was also detected in other tissues of the anterior chamber, such as the endothelial cell layer of the Schlemm’s canal, and the corneal epithelium and stroma, particularly in the area surrounding the injection site. However, there are no indications that these cells compromise the function of the recipient eyes.

Histochemical evaluation of recipient eyes suggested that iPSC-TM treatment results in slight hypertrophy of the TM (Fig. S2). To quantify the number of implanted iPSC-TM and endogenous TM cells in vivo we determined both the number of total nuclei in the TM as well as the number of nuclei of dsRed immunopositive cells in all experimental groups. Here, the TM was defined as the collagen IV immunoreactive tissue overlying the Schlemm’s canal. As expected, vehicle control animals exhibited a marked loss of TM cell density compared with WT animals (25.7 ± 7.3 TM per section vs. 57.1 ± 12.1 TM per section, \( P = 0.00014 \)) (Fig. 5B). Injection of fibroblasts again resulted in a slight improvement, but did not result in a significant increase (38.7 ± 1.5 TM per section, \( P = 0.09 \)). In contrast, the cellular density of the TM in transgenic iPSC-TM recipient mice was significantly higher than that of vehicle controls (54.9 ± 7.2 TM per section, \( P = 6.83E-06 \)) and similar to that of WT animals. Interestingly, although sections of iPSC-TM recipient mice contained on average 29.3 more cells per...
section than those of animals having received PBS injection, we observed on average only 5.9 dsRed cells in each of the sections. This finding suggests that the majority of the additional cells observed in iPSC-TM recipients are not transplanted; rather, they are endogenous cells that have either survived or were replaced through division of the remaining cells.

**Proproliferative Effect of iPSC-TM in Vitro.** To determine if iPSC-TM exert a proproliferative effect on normal mouse pTM cells, we conducted a series of in vitro experiments. Cultures of pTM (27) were infected with adenoviral vectors expressing the same myocilin construct as in the transgenic mice (Ad5RSV-myocilinY437H). Expression of this mutated protein has been reported to result in cellular stress and reduced cell survival (35–37).

Concurrent with these findings, we observed slightly reduced growth rates in transfected pTM cells (Fig. 6A): 50,000 untreated pTM cultured in media alone proliferated to 81,558 ± 4,038 cells within 4 d. The growth rate of pTM infected with Ad5RSV-myocilinY437H is slightly reduced compared with the control (69.383 ± 3.017 or 85.1%, P = 0.032). However, when Ad5RSV-myocilinY437H-infected pTM were cultured in direct contact with iPSC-TM, they exhibited distinctly higher growth rates than the control cells. Cultures seeded with 50,000 Ad5RSV-myocilinY437H-infected pTM maintained either in unconditioned media or media conditioned through coculture with iPSC-TM exhibit replication rates similar to control cells (83.4% and 99.8% of control, respectively).

The notion that direct contact with iPSC-TM leads to enhanced proliferation of pTM was further supported by analysis of incorporation rates of the thymidine analog BrdU (Fig. 6C). In the absence of iPSC-TM 21.3% ± 8.2 of pTM are BrdU+ after 2 h, whereas coculture increases this fraction to 32.8% ± 12.4 of all (dsRed) pTM (P = 0.032). These data indicate that direct contact between iPSC-TM and the target cell is required to initiate enhanced proliferation rates in pTM.

**In Vivo Transcriptional Analysis.** The above findings suggest that the observed functional rescue in Tg-myocilinY437H mice is a result of the re-entry of normally nonmitotic endogenous TM into cell division following stimulation by iPSC-TM. To further support this hypothesis and to gather evidence for proliferation in our in vivo model, we carried out a global gene-expression analysis of the TM of Tg-myocilinY437H mice harvested 12 wk after receiving iPSC-TM, fibroblasts, or vehicle control injections. A total of 879 genes exceeded the cut-off criteria (expression fold-change > 1.5 and P < 0.01) and grouped into 83 clusters based upon their expression profile (Fig. 7A). For subsequent Gene Ontology analysis, only genes assigned to clusters containing at least three genes and with a confidence value above 28 were selected (Fig. 7B). Analysis of these 792 genes by the Panther Classification System (38) identified 265 genes whose functions are related to cellular processes, including cell communication (129 genes) and cell cycle (56 genes) (Dataset S1). These data add further support to the notion that the presence of iPSC-TM induces proliferation and that this effect can be maintained for an extended period.

**Discussion.** The IOP depends on the balance between aqueous humor production by the ciliary body and drainage through the TM. In the normal eye, resident endothelial cells of the TM maintain its structure by continuous remodeling the TM beams and by degrading debris that might otherwise accumulate and occlude the outflow pathways. Loss of TM cells has been suspected to contribute to aqueous humor outflow deficiencies and, conversely, it has been hypothesized that replacing lost cells can restore function to the eye (39). Previous studies by this and other laboratories have indicated that either multipotent cells isolated from the TM (40, 41) or iPSC may be useful for this purpose (23, 42). Indeed, recently published data have indicated that iPSC can restore some functional aspects in an organ culture system. Our study demonstrates that TM-like cells, derived from iPSC, can functionally rescue a glaucoma phenotype in mice. These studies were aimed to a large degree by the availability of the myocilin mouse model of glaucoma. As previously described, these transgenic animals express a pathogenic form of human myocilin, which causes endoplasmic reticulum stress, TM cellular dysfunction, and cell loss (23). However, the animal model, excluding the TM, develops normally in these mice and disturbances in aqueous humor outflow dynamics only become apparent as the animals age. Importantly, similar to human POAG, the pathophysiological events leading to reduced aqueous humor outflow are not associated with gross morphological disruption of the aqueous humor drainage structures, as is the case in many surgically induced models or those resulting from congenital anterior segment malformation (33, 43).

Thus, we reasoned that the TM in these mice will be amenable to restoration. For the reported studies 4-mo-old recipient animals were chosen. At this age, the first signs of a disturbance in the aqueous humor dynamics become apparent in some individuals, including modest elevation of IOP and decreased outflow facility. In untreated mice, the symptoms worsen over the next few weeks and, at the age of 6 mo, the vast majority of transgenic mice develop mildly elevated IOP, significantly reduced aqueous humor outflow facility, and a clear reduction in TM cellularity.

Our data demonstrate that transplantation of iPSC-TM into the eyes of 4-mo-old Tg-MYOCY437H mice prevents the development of elevated IOP and preserves normal aqueous humor normal outflow facility for at least 9 wk. This effect cannot be achieved through transplantation of fibroblasts. These cells would represent a convenient source of patient-derived material and secrete growth factors, such as EGF and PDGF, that stimulate TM cell proliferation (44, 45). Furthermore, fibroblasts closely resemble mesenchymal stromal cells that have shown promise in laser-induced models of glaucoma (46, 47). Our findings indicate that these cells are not inert and improve TM function to some degree. However, a statistically
significant rescue effect cannot be demonstrated. Importantly, the prevention of RGC loss, which is the ultimate cause of vision loss in glaucoma, can only be demonstrated in iPSC-TM treated eyes.

Immunohistochemical evaluation of the anterior segment of treated and control eyes revealed that transplanted iPSC-TM frequently become established in the TM of recipient eyes and survive for at least 12 wk. Transplanted cells were also observed in other tissues of the anterior segment, in particular the iris and corneal endothelium, but this did not noticeably impair these tissues. Furthermore, whereas early transplantation attempts using iPSC-TM populations containing small amounts of cells retaining expression of SSEA-1 frequently led to the formation of ocular tumors, the scrupulous removal of any such cells prove to be a viable and safe approach.

In the adult eye, TM cells do not proliferate under normal circumstances. One possible scenario how iPSC-TM might achieve functional restoration of the TM may be that the transplanted cells establish themselves within the tissue and carry out functions typically carried out by the endogenous cells. It is conceivable that, at least in part, this is also the case here. However, although we observed a strikingly higher TM cell density in transplanted eyes compared with control eyes, the majority of these additional cells are not iPSC-TM, but are derived through division of the recipient eyes’ endogenous TM cells. Thus, a significant benefit of iPSC-TM transplantation is that this process causes endogenous TM cells to re-enter the cell cycle and replace previously lost cells. Accordingly, we detected increased expression of a number of genes associated with cellular division in eyes having received iPSC-TM. This proliferation-enhancing effect of iPSC-TM can also be demonstrated in vitro. Coculture of pTM cells with iPSC-TM results in significantly higher proliferation rates than those observed in pTM alone. Although the mechanism remains currently unresolved, our data demonstrate that it requires cell-cell contact as coculture of physically separated iPSC-TM, and pTM does not replicate the effect.

It is interesting to note that earlier studies examining the physiological consequences of laser trabeculoplasty, a treatment approach using mild laser stimulation of the TM, had also noted an increase in the number of TM cells in the treated areas that the investigators had speculated might be the cause of improved aqueous humor outflow (21, 22). The newly derived TM cells are derived from a population of progenitor cells located directly beneath the Schwalbe’s line that are suspected to resemble stem cells (48). It is intriguing to speculate whether the endogenous TM cells re-entering the cell cycle following iPSC-TM transplantation belong to this particular TM cell subtype. On the other hand, the normally postmitotic TM cells of the adult eye retain some proliferative properties and readily divide in vitro. Thus, it is conceivable that iPSC-TM-mediated signaling removes proliferative inhibition and causes cell division in vivo.

Although these studies are very encouraging, a number of questions remain. For example, because the functional restoration appears to depend upon proliferation of endogenous TM cells, which also express MYOC<sup>Y437H</sup>, it is possible that these newly derived cells are themselves eventually lost resulting in a gradual return of outflow dysfunction. Although in theory eyes can be retreated with iPSC-TM, the influence of advanced age is currently unclear. It is conceivable that this approach is less successful in very old eyes. These considerations may be less of a concern in cases of open angle glaucoma that are not the result of this very aggressive mutation, because TM cell loss typically occurs over many decades and, assuming similar rates of cell loss, newly derived TM cells may survive for many years. However, additional studies will have to be carried out to determine whether this approach can be successfully used to reverse aqueous humor outflow deficiencies in other animal models or in other types of glaucoma. We are confident that the TM cell loss exhibited in our mouse model shares many important features with general POAG. Other types of glaucoma (e.g., that associated with pseudoexfoliation syndrome) result from dissimilar damage to the TM, and it will be interesting to determine if our approach will also be beneficial in these cases.

**Materials and Methods**

Additional experimental details are included in SI Materials and Methods and Tables S1–S3.
Mice. Tg-MYODεY437H breeder mice were maintained on a C57BL/6J background. Experimental animals were generated by crosses between these and SJL/J mice and only F1 animals were used.

**Generation and Differentiation of iPSC.** Mouse iPSC were generated by reprogramming fifth passage fibroblasts of 6-wk-old transgenic mice expressing the marker protein dsRed [B6.Cg-Tg(ACBT-DsRed*M1TmGlyl) Jackson Laboratory] using a set of ectropic retrovirus (mouse OKSM), as described previously (49, 50). Mouse iPSC were cultured on 0.2% matrigel coated plates in mouse iPSC media [DMEM/F12, 15% (vol/vol) heat-inactivated FBS, 1% NEAA, 1% g-glutamine, 1% PenStrep, 0.2% Fungizone, 0.0008% BME], which was exchanged daily.

Mouse iPSC were differentiated through culture in media preconditioned by human pTMT. Briefly, human pTMT were isolated from the TM of donor eyes, as described previously (51) and cultured in Biopsy media (MEMα, 10% inactivated FBS, 0.2% primocin). The media conditioned by these pTMT was collected daily, pooled, and sterilized by filtration through MCE membrane filters (0.2-μm pore size; Millipore). Sterilized conditioned media was used to induce iPSC to differentiate since the confluence of iPSC reached 5% and the media was exchanged daily.

**Induction of CLANs.** Mouse iPSC were differentiated for 14 d and then exposed with 100 nM Dex for 3 d. Control cells were treated with 1% ethanol (vehicle control). Cells were stained with Alexa Fluor 647 Phalloidin and 100x images were taken from each sample. Nuclei of all iPSC-TM forming CLANs, defined as cytoskeletal structures as geodesic dome-like polygonal lattices in dome-shaped cells, were counted and compared with the fraction of all iPSC-TM present.

**Purification of iPSC-TM.** Following 14 d of differentiation, 107 cells were trypanosized, resuspended and incubated with magnetic microbeads conjugated to SSEA-1 (CD15) antibodies (Miltenyi Biotec). Cells were washed and loaded into a MACS LD column placed in the magnetic separator (Miltenyi Biotec). See SI Materials and Methods for details.

**iPSC Transplantation.** Mice were deep anesthetized using a ketamine/xylazine mixture (87.5 mg/kg ketamine and 12.5 mg/kg xylazine). Next, 50,000 iPSC-TM in 3 μL PBS were injected into the anterior chamber through the cornea in the limbal region using 33-gauge half-inch stainless steel needles. Immediately before injection, a small amount of aqueous humor was allowed to escape to accommodate the injected volume. An equal volume of PBS was injected in the control group. GenTeal Severe Dry Eye Relief Lubricant was applied on the surface of the cornea after the injections to avoid excessive drying during the anesthesia.

**IOP Measurements.** IOP was measured between 9:00 AM to 12:00 PM using a programmable pump. Data were only considered if a stable measurement was attained at all pressure steps and a r2 value > 0.95 was reached. To minimize the number of manipulations carried out on each eye, not all transplanted eyes were assessed at all time points.

**Immunohistochemistry.** Cells were grown on coverslips and fixed in 4% (wt/vol) paraformaldehyde for 20 min. Animal tissues were fixed in 4% paraformaldehyde for 4 h, embedded in OCT, frozen, and sectioned to 10-μm thickness on a cryostat. See SI Materials and Methods for additional details.

**Morphometric Studies.** To count dsRed iPSC-TM cells and endogenous TM cells in vivo, anterior chambers were sectioned to 10-μm thickness. TM tissues were identified by collagen IV immunoactivity (Abcam) and ipSC-TM cells were labeled with dsRed antibody (Santa Cruz). Nuclei were stained using 0.1 μg/mL DAPI (Life Technologies). For each sample, nuclei of iPSC-TM cells and endogenous TM cells from nine sections were counted and the numbers were averaged. To determine RGC density, eyes were enucleated and retinas were carefully dissected. Retinas were incubated overnight with antibodies directed against γ-synuclein (Abnova). After several rinses and the application of donkey anti-mouse secondary antibody (Life Technologies), retinas were whole-mounted. Eight 40x images each representing an area of 318 × 318 μm2 were taken at predetermined locations representing the whole retina. RGC were counted in each image and data were averaged. One caveat of this approach is that only γ-synuclein RGC are identified.

**In Vitro Studies.** Mouse pTMT were transfected with adenoviral vectors expressing either a pathogenic form of human α-synuclein (AdSRSSVmycIn23YH-HisFlag) or empty AdSCMV (control). The effects of cell-cell contact with iPSC-TM and pTMT was determined by seeding 50,000 purified iPSC-TM cells in transwell inserts above 50,000 mouse pTMT. Alternatively, 50,000 mouse pTMT were maintained in the presence of 50,000 iPSC-TM. The number of surviving cells was determined using flow cytometry analysis.

**Statistical Analysis.** Student’s t test was used for statistical evaluation between two groups. P values < 0.05 were considered to be significant throughout this investigation.

**Study Approval.** All animal experimentation was carried out in accordance with the NIH Guide for the Care and Use of Laboratory Animals (75) and all protocols were reviewed and approved by the University of Iowa committee on Animal Care and Use.
14. Tektas OY, Lütjen-Drecoll E (2009) Structural changes of the trabecular meshwork in different kinds of glaucoma. *Exp Eye Res* 88(4):769–775.

15. Grierson I, Hogg P (1995) The proliferative and migratory activities of trabecular meshwork cells. *Prog Retin Eye Res* 15(1):33–67.

16. Rodrigues MM, Spaeth GL, Sivalingam E, Weinreb R (1976) Histopathology of 150 trabeculectomy specimens in glaucoma. *Trans Ophthalmol Soc U K* 96(2):245–255.

17. Alvarado J, Murphy C, Juster R (1984) Trabecular meshwork cellularity in primary open-angle glaucoma and nonglaucomatous normals. *Ophthalmology* 91(6):564–579.

18. Gottanka J, Johnson DH, Grehn F, Lütjen-Drecoll E (2006) Histologic findings in pigment dispersion syndrome and pigmentary glaucoma. *J Glaucoma* 15(2):142–151.

19. Alexander RA, Grierson I (1989) Morphological effects of argon laser trabeculoplasty upon the glaucomatous human meshwork. *Eye (Lond)* 3(PT 6):719–726.

20. Van Buskirk EM (1989) Pathophysiology of laser trabeculoplasty. *Surv Ophthalmol* 33(4):264–272.

21. Acott TS, et al. (1989) Trabecular repopulation by anterior trabecular meshwork cells after laser trabeculoplasty. *Am J Ophthalmol* 107(1):1–6.

22. Dueker DK, Norberg M, Johnson DH, Tschumper RC, Feneey-Burns L (1990) Stimulation of cell division by argon and Nd:YAG laser trabeculoplasty in cynomolgus monkeys. *Invest Ophthalmol Vis Sci* 31(1):115–124.

23. Ding QJ, et al. (2014) Induction of trabecular meshwork mesenchymal stem cells. *Invest Ophthalmol Vis Sci* 55(11):7065–7072.

24. Zode GS, et al. (2011) Reduction of ER stress via a chemical chaperone prevents disease phenotypes in a mouse model of primary open angle glaucoma. *J Clin Invest* 121(9):3542–3553.

25. Beckel JM, et al. (2014) Mechanosensitive release of adenosine 5'-triphosphate through pannexin channels and mechanosensitive upregulation of pannexin channels in optic nerve head astrocytes: A mechanism for purinergic involvement in chronic strain. *Glia* 62(8):1486–1501.

26. Clark AF, et al. (1994) Glucocorticoid-induced formation of cross-linked actin network in cultured human trabecular meshwork cells. *Invest Ophthalmol Vis Sci* 35(1):281–294.

27. Mao W, Liu Y, Wordinger RJ, Clark AF (2013) A magnetic bead-based method for mouse trabecular meshwork cell isolation. *Invest Ophthalmol Vis Sci* 54(5):3600–3606.

28. Millar JC, Phan TN, Pang IH, Clark AF (2015) Strain and age effects on aqueous humor dynamics in the mouse. *Invest Ophthalmol Vis Sci* 56(10):5764–5776.

29. Ding QJ, Cook AC, Dumitrescu AV, Kuehn MH (2012) Lack of immunoglobulins does not prevent C1q binding to RGC and does not alter the progression of experimental glaucoma. *Invest Ophthalmol Vis Sci* 53(10):6370–6377.

30. Gramlick WR, et al. (2015) Adoptive transfer of immune cells from glaucomatous mice provokes retinal ganglion cell loss in recipients. *Acta Neuropathol Commun* 3:56.

31. Harper MM, et al. (2011) Transplantation of BDNF-secreting mesenchymal stem cells provides neuroprotection in chronically hypertensive rat eyes. *Invest Ophthalmol Vis Sci* 52(7):4505–4515.

32. Kuehn MH, Kim CY, Jiang B, Dumitrescu AV, Kwon YH (2008) Disruption of the functional growth factor receptors. *Invest Ophthalmol Vis Sci* 55(9):5838–5845.

33. Boussommier-Calleja A, et al. (2012) Pharmacologic manipulation of conventional outflow facility in ex vivo mouse eyes. *Invest Ophthalmol Vis Sci* 53(9):5838–5845.

34. Camras LJ, et al. (2010) Duration of anesthesia affects intraocular pressure, but not strain. *Invest Ophthalmol Vis Sci* 51(11):7499–7507.

35. Tucker BA, Anfinson KR, Mullins RF, Stone EM, Young MJ (2013) Use of a synthetic xeno-free culture substrate for induced pluripotent stem cell induction and retinal differentiation. *Stem Cells Transl Med* 2(1):16–24.

36. Tucker BA, et al. (2011) Transplantation of adult mouse iPSC-derived photoreceptor precursors restores retinal structure and function in degenerative mice. *PLoS One* 6(4):e18992.

37. Stamer WD, Seftor RE, Williams SK, Samaha HA, Snyder RW (1995) Isolation and culture of human trabecular meshwork cells by extracellular matrix digestion. *Curr Eye Res* 14(7):611–617.

38. Kuehn MH, et al. (2006) Retinal synthesis and deposition of complement components induced by ocular hypertension. *Exp Eye Res* 83(3):620–628.

39. Quigley HA, et al. (2011) Lack of neuroprotection against experimental glaucoma in c-Jun N-terminal kinase 3 knockout mice. *Exp Eye Res* 92(4):299–305.

40. Alvarado J, Murphy C, Juster R (1984) Trabecular meshwork cellularity in primary open-angle glaucoma and nonglaucomatous normals. *Ophthalmology* 91(6):564–579.

41. Kelley MJ, et al. (2009) Stem cells in the trabecular meshwork: Present and future promises. *Exp Eye Res* 88(4):747–751.

42. Du Y, et al. (2012) Multipotent stem cells from trabecular meshwork become phagocytic TM cells. *Invest Ophthalmol Vis Sci* 53(3):1566–1575.

43. Yu Y, Yun H, Yang E, Schuman JS (2013) Stem cells from trabecular meshwork home to TM tissue in vivo. *Invest Ophthalmol Vis Sci* 54(2):1450–1459.

44. Abu-Hassan DW, Li X, Ryan EJ, Acott TS, Kelley MJ (2015) Induced pluripotent stem cells restore function in a human cell loss model of open-angle glaucoma. *Stem Cells* 33(3):751–761.

45. Mao M, Hedberg-Bueen A, Koehn D, John SW, Anderson MG (2011) Anterior segment dysgenesis and early-onset glaucoma in neo mice with mutation of Sh3pxd2b. *Invest Ophthalmol Vis Sci* 52(5):2679–2688.

46. Howard M, Szipi-Keiser M (2006) Fibroblasts in cancer. *Nat Rev Cancer* 6(5):392–401.

47. Wordinger RJ, et al. (1998) Conventional human trabecular meshwork cells express functional growth factor receptors. *Invest Ophthalmol Vis Sci* 39(9):1575–1589.

48. Hematti P (2012) Mesenchymal stromal cells and fibroblasts: A case of mistaken identity? *Cytotherapy* 14(5):516–521.

49. Roubeix C, et al. (2015) Intracocular pressure reduction and neuroprotection conferred by bone marrow-derived mesenchymal stem cells in an animal model of glaucoma. *Stem Cell Res Ther* 6:177.

50. Graus-Blay J, et al. (2013) Identification of adult stem cells in Schwalbe’s line region of the primate eye. *Invest Ophthalmol Vis Sci* 55(11):7499–7507.

51. Stamer WD, Seftor RE, Williams SK, Samaha HA, Snyder RW (1995) Isolation and culture of human trabecular meshwork cells by extracellular matrix digestion. *Curr Eye Res* 14(7):611–617.

52. Kim CY, Kuehn MH, Anderson MG, Kwon YH (2007) Intracocular pressure measurement in mice: A comparison between Goldmann and rebound tonometry. *Eye (Lond)* 21(9):1202–1209.

53. Camras LJ, et al. (2010) Duration of anesthesia affects intraocular pressure, but not outflow facility in mice. *Curr Eye Res* 35(9):819–827.

54. Kuehn MH, Kim CY, Jiang B, Dumitrescu AV, Kwon YH (2008) Disruption of the complement cascade delays retinal ganglion cell death following retinal ischemia-reperfusion. *Exp Eye Res* 87(2):89–95.

55. Kuehn MH, et al. (2006) Retinal synthesis and deposition of complement components induced by ocular hypertension. *Exp Eye Res* 83(3):620–628.

56. Quigley HA, et al. (2011) Lack of neuroprotection against experimental glaucoma in c-Jun N-terminal kinase 3 knockout mice. *Exp Eye Res* 92(4):299–305.

57. Committee on Care and Use of Laboratory Animals (1996) *Guide for the Care and Use of Laboratory Animals* (National Institutes of Health, Bethesda, MD), DHHS Publ No (NIH) 85-23.